Paediatric colistin prescribing practices in South Africa: A clinician survey
Authors:
- Veshni Pillay-Fuentes LorenteVeshni Pillay-Fuentes Lorente
- Trusha NanaTrusha Nana
- Marianne BlackMBMarianne Black
- Gary ReubensonGary Reubenson
- Reenu ThomasReenu Thomas
- Angela DramowskiAngela Dramowski
- Adrie BekkerAdrie Bekker
- Nicolette Du PlessisNicolette Du Plessis
- Despina DemopoulosDDDespina Demopoulos
- Vindana ChibabhaiVindana Chibabhai
Open Access
- 12 December 2024
- journal article
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 40 (1) , 8
Abstract
Background: Increasing multidrug-resistant bacterial infections are a global health challenge. Colistin, a polymyxin antimicrobial, has activity against some resistant strains, and despite its adverse effects, it presents a last-line option to treat resistant Gram-negative pathogens. However, paediatric colistin prescribing guidelines are lacking. Objectives: To determine paediatric colistin prescribing practices and challenges in South Africa (SA) to aid the development of a paediatric colistin guideline. Method: We conducted an anonymous online survey of registered medical practitioners in SA who prescribed colistin to patients aged ≤ 14 years in the past 12 months. Results: Of 196 participants, 71.9% (n = 141/196) completed the survey. Eighty-six respondents (n = 86/146; 58.9%) reported prescribing loading doses (LD), with the median LD and maintenance doses of 150 000 IU/kg/dose (interquartile range (IQR), 75 000–150 000) and 50 000 IU/kg/dose (IQR, 40 000–50 000), respectively. Empiric colistin use was reported by 47.2% (n = 69/146), of whom 46.3% (n = 32/69) continued empiric colistin for ≥ 72 h. Using the Likert scale, respondents highly perceived that therapeutic drug monitoring should be readily available (mean = 3.97). The perception that prescribing colistin should be advised by a microbiologist or infectious disease specialist had a mean score of 2.97, indicating moderate agreement. Conclusion: This survey demonstrated varied paediatric colistin prescribing practices. Recently, a new evidence-based paediatric guideline for colistin use in SA has been published. A follow-up survey will be conducted to assess the impact of the guideline on paediatric colistin prescribing practices in SA. Contribution: This study highlighted paediatric colistin dosing practices in the absence of a paediatric colistin guideline in South Africa.Keywords
This publication has 14 references indexed in Scilit:
- StatPearls2023
- Pharmacokinetics of Antimicrobials in Children with Emphasis on Challenges Faced by Low and Middle Income Countries, a Clinical ReviewAntibiotics, 2022
- Antimicrobial Stewardship in Public-Sector Hospitals in KwaZulu-Natal, South AfricaAntibiotics, 2022
- Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended DosesAntimicrobial Agents and Chemotherapy, 2021
- Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patientsInternational Journal of Antimicrobial Agents, 2020
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- The Surviving Sepsis Campaign Bundle: 2018 updateIntensive Care Medicine, 2018
- Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill NeonatesThe Pediatric Infectious Disease Journal, 2016
- Toxicity of polymyxins: a systematic review of the evidence from old and recent studiesCritical Care, 2006
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005